[Clinical analysis of 14 cases of epithelioid sarcoma].
OBJECTIVE
Epithelioid sarcoma is a rare soft tissue sarcoma with a high propensity for aggressiveness, regional nodal spread, and distant metastases. This study was to investigate the clinical features, diagnosis, treatment, and prognosis of epithelioid sarcoma.


METHODS
The clinical data of 14 patients with epithelioid sarcoma, admitted to our hospital from 1990 to 2005, were analyzed. All of the 14 patients received initial operations at other hospitals. Eleven patients received extensive excision (9 patients) or amputation (2 patients), and 4 of them also received local lymph node dissection at our hospital; 3 patients received another local excision or extensive excision at other hospitals again. Nine patients received adjuvant radiotherapy and 3 of them also received adjuvant chemotherapy.


RESULTS
All diagnoses of epithelioid sarcoma were confirmed by pathology. Of the 14 patients, 12 (85.7%) had local recurrence and 4 (28.6%) had local lymph node metastasis, 9 (64.3%) died within 3 years after initial operation. The overall 1-, 2-, 5-, 10-year survival rates were 71.43%, 55.56%, 27.78%, 13.89%, respectively.


CONCLUSIONS
The prognosis of epithelioid sarcoma is poor because of a high propensity for local recurrence, node metastases, and distant metastases. Extensive excision or radical excision combined local lymph node dissection is effective for epithelioid sarcoma.
Xu
Li-Bin
LB
Department of Orthopedic Surgery, Cancer Hospital/Institute, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, P. R. China. xu_libin@126.com
Yu
Sheng-Ji
SJ
Shao
Yong-Fu
YF
Zhang
Hong-Tu
HT
Zhao
Zhen-Guo
ZG
D000328:Adult; D000671:Amputation, Surgical; D017024:Chemotherapy, Adjuvant; D005121:Extremities / Q000473:pathology* / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D018714:Radiotherapy, Adjuvant; D012509:Sarcoma / Q000473:pathology* / Q000601:surgery* / Q000628:therapy; D012983:Soft Tissue Neoplasms / Q000473:pathology* / Q000601:surgery* / Q000628:therapy; D015996:Survival Rate